Abbott expects to double vascular business sales
13th Nov 2006, 06:59 GMT
Abbott's Bay Area-based vascular division expects to double its $1.4 billion sales in the next three years as its Guidant acquisition thrusts it into the lucrative market for drug-dispensing stents.
Abbott expects to double vascular business sales related news:
- Samsung Expects Strong Q4 Sales — TechNewsWorld
- Onex expects to ‘roughly double our money' on U.S. REIT — The Globe and Mail - Business News
- AP Interview: GE overseas business could pass U.S. sales by 2007 — Boston.com / News
- Abbott Begins Kos Tender Offer — Financial News News from StratCenter.com
- Airline to double its flights as sales soar — Scotsman.com News
- SEC expects to pursue more hedge fund suits — Boston Globe -- Business News
- Smart Cards Spread — eWEEK Developer
- Firms miss out on R&D sales boost — BBC News | Business | Companies | UK Edition
- Andrew Bynum better than Magic? — NBA Player News : CBS SportsLine.com
- Retail sales fall for a second month — MSNBC.com: Business
Latest news from bizjournals.com Health Care:Pharmaceuticals headlines:
- United BioSource makes 10th buy, looks for more
- Nonprofits starting to invest in drug companies
- Accentia making changes to its business formula, market focus
- GSK terminates agreement for Genaera frog product
- Gladstone and Merck team to bring drugs to market
- Mayo to shut down drug-testing unit
- MIT, Dana-Farber win major cancer grants
- Service Bancorp chair resigns
- Introgen strikes nanotech deal with M.D. Anderson
- Joslin spins out first-ever company, Veraxa Health Inc.